Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.
about
Mechanistic insights into nicotine withdrawal.Mouse models for studying genetic influences on factors determining smoking cessation success in humans.Comparison of effects produced by nicotine and the α4β2-selective agonist 5-I-A-85380 on intracranial self-stimulation in rats.Intracranial self-stimulation to evaluate abuse potential of drugs.Anti-relapse medications: preclinical models for drug addiction treatment.Varenicline for tobacco dependence: panacea or plight?Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients.Neurophysiology of Nicotine AddictionAnimal models to assess the abuse liability of tobacco products: effects of smokeless tobacco extracts on intracranial self-stimulation.Allosteric modulators of the α4β2 subtype of neuronal nicotinic acetylcholine receptors.Involvement of neuronal β2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapiesVarenicline dose dependently enhances responding for nonpharmacological reinforcers and attenuates the reinforcement-enhancing effects of nicotine.Effects of nicotine and minor tobacco alkaloids on intracranial-self-stimulation in rats.Addiction and brain reward and antireward pathways.Delivery of nicotine in an extract of a smokeless tobacco product reduces its reinforcement-attenuating and discriminative stimulus effects in ratsElectrophysiology-Based Assays to Detect Subtype-Selective Modulation of Human Nicotinic Acetylcholine ReceptorsEffects of nicotinic acetylcholine receptor agonists in assays of acute pain-stimulated and pain-depressed behaviors in rats.Effects of the specific α4β2 nAChR antagonist, 2-fluoro-3-(4-nitrophenyl) deschloroepibatidine, on nicotine reward-related behaviors in rats and miceThe effects of varenicline on methamphetamine self-administration and drug-primed reinstatement in female rats.A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats.Animal models of nicotine exposure: relevance to second-hand smoking, electronic cigarette use, and compulsive smoking.Mechanism-based medication development for the treatment of nicotine dependence.Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats.Abuse liability assessment of an e-cigarette refill liquid using intracranial self-stimulation and self-administration models in rats.The cytisine derivatives, CC4 and CC26, reduce nicotine-induced conditioned place preference in zebrafish by acting on heteromeric neuronal nicotinic acetylcholine receptors.Single dose varenicline may trigger epileptic activity.Effects of nicotine-containing and "nicotine-free" e-cigarette refill liquids on intracranial self-stimulation in rats.Similar precipitated withdrawal effects on intracranial self-stimulation during chronic infusion of an e-cigarette liquid or nicotine alone.Status and Future Directions of Preclinical Behavioral Pharmacology in Tobacco Regulatory Science
P2860
Q27687645-57E6CC47-6E28-4405-BA99-C2936DB0CFACQ30432964-24CBF543-96FD-44D5-B4BF-2B8A6FC0FA3EQ30738165-D763A55A-464B-45E4-8D58-D2EF84CE94BFQ33845750-1F9E269D-D4AB-4EFD-A33C-26E526FA16B0Q33927470-F9E58433-5904-49F1-B211-6582146131EFQ34190097-077C3BB6-6E6A-430D-9651-45855520E1C3Q34526371-0091AE95-465D-45DF-B8CA-8CC204B745C9Q34637004-756B6991-C962-4943-B846-CD849ED9B70AQ35110020-FA1498D4-37FD-4F3B-BE51-8C475850250EQ35182101-E548F64E-E8B4-4928-8150-9632BDEE0D7AQ35694111-3D3C9F12-F7DA-453D-9E76-8F4B1C511F10Q35761753-AFFE8D1F-0C59-4802-B24F-B83961100A9EQ35875970-B1554D44-60ED-4720-8D09-6FA9C6E14056Q35995170-14C789CB-E7D9-46AA-9C01-FFA4E558B523Q35997407-BEB41308-5649-45EB-9F6E-5F5F8E6CEAA5Q36098807-85906976-4422-4E0D-BE83-70D904CD4D4EQ36186198-3F84CCD7-C43C-4523-82B1-BD9B5F5BD050Q36298187-E4D1E5A6-BCE0-4575-A5BF-5BCD7B51CCFAQ36494806-0102AF05-8077-43BF-B912-C09F85D0AA20Q36696626-0484185C-5083-4360-B2C1-80BAE4772CC3Q36900018-9EEBACA0-4EEB-48F9-AE2F-3B1E572A3920Q37018610-7BF7B6F3-76A9-4DD2-B67A-ABFC192FCAA0Q37409561-D9C63BBB-2C1B-41A7-92EC-6330DF428E9EQ43055981-A2CC4EEA-695B-4FFE-91A1-B69AA32FDDA5Q47073739-1430F853-7F64-44BE-8DE5-184F7631548CQ48729080-9592A874-A3A2-4141-AA1E-F7D792C55BB0Q50138553-F58AB65C-DBB7-4B28-B40D-E463447853B4Q50228727-FF493B2C-318D-43DD-85CE-7BFA32C2EA5BQ57171561-EB190126-8164-4952-B1A2-E5F231957562
P2860
Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Varenicline attenuates nicotin ...... 2 nicotinic receptors in rats.
@en
Varenicline attenuates nicotin ...... 2 nicotinic receptors in rats.
@nl
type
label
Varenicline attenuates nicotin ...... 2 nicotinic receptors in rats.
@en
Varenicline attenuates nicotin ...... 2 nicotinic receptors in rats.
@nl
prefLabel
Varenicline attenuates nicotin ...... 2 nicotinic receptors in rats.
@en
Varenicline attenuates nicotin ...... 2 nicotinic receptors in rats.
@nl
P2093
P2860
P1433
P1476
Varenicline attenuates nicotin ...... a2 nicotinic receptors in rats
@en
P2093
Ashok Tehim
Charles R Ashby
Eliot L Gardner
Patrick M Callahan
Zheng-Xiong Xi
P2860
P356
10.1016/J.NEUROPHARM.2009.04.006
P577
2009-04-22T00:00:00Z